Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application

J Control Release. 2014 Feb 28:176:123-132. doi: 10.1016/j.jconrel.2013.12.019. Epub 2013 Dec 27.

Abstract

Red blood cells (RBCs) based drug carrier appears to be the most appealing for protein drugs due to their unmatched biocompatability, biodegradability, and long lifespan in the circulation. Numerous methods for encapsulating protein drugs into RBCs were developed, however, most of them induce partial disruption of the cell membrane, resulting in irreversible alterations in both physical and chemical properties of RBCs. Herein, we introduce a novel method for encapsulating proteins into intact RBCs, which was meditated by a cell penetrating peptide (CPP) developed in our lab-low molecular weight protamine (LMWP). l-asparaginase, one of the primary drugs used in treatment of acute lymphoblastic leukemia (ALL), was chosen as a model protein to illustrate the encapsulation into erythrocytes mediated by CPPs. In addition current treatment of ALL using different l-asparaginase delivery and encapsulation methods as well as their associated problems were also reviewed.

Keywords: Acute lymphoblastic leukemia; Cell penetrating peptide; Encapsulation; Erythrocytes; Red blood cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Asparaginase / administration & dosage
  • Cell-Penetrating Peptides / administration & dosage*
  • Drug Carriers / administration & dosage*
  • Erythrocytes*
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

Substances

  • Antineoplastic Agents
  • Cell-Penetrating Peptides
  • Drug Carriers
  • Asparaginase